# Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

> **NCT04006704** · PHASE1 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 25 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** D/C/F/TAF FDC placebo

## Key facts

- **NCT ID:** NCT04006704
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-10
- **Primary completion:** 2020-03-06
- **Final completion:** 2020-03-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006704, "Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04006704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*